Amgen Ranks as Top 25 Dividend Giant with 3.21% Yield
PorAinvest
lunes, 4 de agosto de 2025, 9:24 am ET1 min de lectura
AMGN--
Amgen Inc. has been recognized as a Top 25 "Dividend Giant" by ETF Channel, with $32.91 billion worth of stock held by ETFs and a 3.21% yield. The company's strong quarterly dividend history and favorable long-term growth rates in key fundamental data points have contributed to this distinction.
The annualized dividend for Amgen Inc. is $9.52 per share, paid quarterly. The most recent dividend ex-date was August 22, 2025. Amgen's dividend payout ratio (DPR) is currently at 86.86%, indicating a robust dividend distribution to shareholders.
Institutional investors have shown strong interest in Amgen Inc. Argent Trust Co, for instance, increased its stake in Amgen by 4.4% during the first quarter of 2025, acquiring an additional 1,097 shares and bringing its total holdings to 26,114 shares valued at approximately $8.14 million [2].
Amgen Inc. reported earnings per share (EPS) of $4.90 for the most recent quarter, exceeding analysts' expectations of $4.18 and achieving a revenue increase of 9.4% compared to the previous year. The company's revenue for the quarter was up 9.4% compared to the same quarter last year, reaching $8.15 billion [2].
Research analysts have provided a mixed outlook on Amgen Inc. Mizuho increased their price target on Amgen from $235.00 to $280.00 and gave the company a "neutral" rating. Guggenheim issued a "neutral" rating and a $288.00 price target on the stock. UBS Group raised their price target on Amgen from $315.00 to $326.00 and gave the stock a "neutral" rating. Royal Bank Of Canada reduced their price target on Amgen from $324.00 to $320.00 and set an "outperform" rating on the stock. Citigroup raised their price target on Amgen from $300.00 to $305.00 and gave the stock a "neutral" rating [2].
Amgen Inc. has a market capitalization of $159.64 billion, a PE ratio of 27.09, a PEG ratio of 2.57, and a beta of 0.49. The company has a current ratio of 1.17, a quick ratio of 0.88, and a debt-to-equity ratio of 8.70 [1].
Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $339.17. The company's fifty-day moving average price is $292.04 and its 200-day moving average price is $292.03 [1].
Amgen Inc. has a consensus rating of "Hold" and an average target price of $307.27 [2].
References
[1] https://stockanalysis.com/stocks/amgn/dividend/
[2] https://www.marketbeat.com/instant-alerts/filing-argent-trust-co-acquires-1097-shares-of-amgen-inc-nasdaqamgn-2025-08-03/
C--
MFG--
RY--
UBS--
Amgen Inc. has been named a Top 25 "Dividend Giant" by ETF Channel with $32.91B worth of stock held by ETFs and a 3.21% yield. The company has a strong quarterly dividend history and favorable long-term growth rates in key fundamental data points. The annualized dividend is $9.52/share, paid quarterly, with the most recent dividend ex-date on 08/22/2025.
Title: Amgen Inc. Named a Top 25 "Dividend Giant" by ETF ChannelAmgen Inc. has been recognized as a Top 25 "Dividend Giant" by ETF Channel, with $32.91 billion worth of stock held by ETFs and a 3.21% yield. The company's strong quarterly dividend history and favorable long-term growth rates in key fundamental data points have contributed to this distinction.
The annualized dividend for Amgen Inc. is $9.52 per share, paid quarterly. The most recent dividend ex-date was August 22, 2025. Amgen's dividend payout ratio (DPR) is currently at 86.86%, indicating a robust dividend distribution to shareholders.
Institutional investors have shown strong interest in Amgen Inc. Argent Trust Co, for instance, increased its stake in Amgen by 4.4% during the first quarter of 2025, acquiring an additional 1,097 shares and bringing its total holdings to 26,114 shares valued at approximately $8.14 million [2].
Amgen Inc. reported earnings per share (EPS) of $4.90 for the most recent quarter, exceeding analysts' expectations of $4.18 and achieving a revenue increase of 9.4% compared to the previous year. The company's revenue for the quarter was up 9.4% compared to the same quarter last year, reaching $8.15 billion [2].
Research analysts have provided a mixed outlook on Amgen Inc. Mizuho increased their price target on Amgen from $235.00 to $280.00 and gave the company a "neutral" rating. Guggenheim issued a "neutral" rating and a $288.00 price target on the stock. UBS Group raised their price target on Amgen from $315.00 to $326.00 and gave the stock a "neutral" rating. Royal Bank Of Canada reduced their price target on Amgen from $324.00 to $320.00 and set an "outperform" rating on the stock. Citigroup raised their price target on Amgen from $300.00 to $305.00 and gave the stock a "neutral" rating [2].
Amgen Inc. has a market capitalization of $159.64 billion, a PE ratio of 27.09, a PEG ratio of 2.57, and a beta of 0.49. The company has a current ratio of 1.17, a quick ratio of 0.88, and a debt-to-equity ratio of 8.70 [1].
Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $339.17. The company's fifty-day moving average price is $292.04 and its 200-day moving average price is $292.03 [1].
Amgen Inc. has a consensus rating of "Hold" and an average target price of $307.27 [2].
References
[1] https://stockanalysis.com/stocks/amgn/dividend/
[2] https://www.marketbeat.com/instant-alerts/filing-argent-trust-co-acquires-1097-shares-of-amgen-inc-nasdaqamgn-2025-08-03/

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios